医学
安慰剂
内科学
耐受性
临床终点
人口
红斑狼疮
置信区间
不利影响
随机对照试验
免疫学
病理
抗体
环境卫生
替代医学
作者
Yoshiya Tanaka,Tatsuya Atsumi,Masato Okada,Tomoya Miyamura,Tomonori Ishii,Susumu Nishiyama,Ryutaro Matsumura,Nobuya Hayashi,Gabriel Abreu,Raj Tummala,Eric F. Morand,Tsutomu Takeuchi
摘要
The efficacy and safety of anifrolumab 300 mg in Japanese patients with SLE was consistent with the demonstrated clinical profile of anifrolumab for the overall TULIP-2 population.
科研通智能强力驱动
Strongly Powered by AbleSci AI